Haga Hospital
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
The Hematology unit at Haga Hospital conducts research aimed at improving outcomes for patients with blood‑related cancers and lymphomas, testing innovative immunotherapies and targeted agents to extend survival.
- Acute Myeloid Leukemia
- Diffuse Large B‑Cell Lymphoma
- Hodgkin lymphoma
- high risk diffuse large B‑cell lymphoma
- MDS‑EB2
Ongoing studies evaluate novel consolidation strategies and combination regimens to increase disease‑free survival and reduce relapse rates.
Neoplasms
In the oncology spectrum, the site explores treatments for solid tumors such as Breast Neoplasms, seeking to improve recurrence prevention through endocrine therapy alternatives.
- Breast Neoplasms
Clinical work emphasizes personalized hormone‑targeted approaches and comparative effectiveness research to enhance long‑term disease control.
Integrated Hematology Research
Across its five trials, Haga Hospital investigates cutting‑edge therapies for both blood cancers and solid tumors, with a focus on extending progression‑free and overall survival.
- Acute Myeloid Leukemia
- Breast Neoplasms
- Diffuse Large B‑Cell Lymphoma
- Hodgkin lymphoma
- MDS‑EB2
- high risk diffuse large B‑cell lymphoma
The collaborative effort of ten investigators supports rapid translation of promising agents into clinical practice, aiming to set new standards of care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Universitaetsklinikum Ulm AöR1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Haga Hospital
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| HOVON 151 DLBCL: A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diffuse large B-cell lymphoma. | Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting | Phase II | Not Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atezolizumab | 1 | Unknown | 2018-08-28 | 2018-08-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.